JP2024546877A5 - - Google Patents
Info
- Publication number
- JP2024546877A5 JP2024546877A5 JP2024535545A JP2024535545A JP2024546877A5 JP 2024546877 A5 JP2024546877 A5 JP 2024546877A5 JP 2024535545 A JP2024535545 A JP 2024535545A JP 2024535545 A JP2024535545 A JP 2024535545A JP 2024546877 A5 JP2024546877 A5 JP 2024546877A5
- Authority
- JP
- Japan
- Prior art keywords
- relaxin
- section
- chain
- heterodimer fusion
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163289687P | 2021-12-15 | 2021-12-15 | |
| US63/289,687 | 2021-12-15 | ||
| US202263386812P | 2022-12-09 | 2022-12-09 | |
| US63/386,812 | 2022-12-09 | ||
| PCT/EP2022/086001 WO2023111112A1 (en) | 2021-12-15 | 2022-12-14 | Treatment using heterodimeric relaxin fusions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546877A JP2024546877A (ja) | 2024-12-26 |
| JP2024546877A5 true JP2024546877A5 (https=) | 2025-12-24 |
Family
ID=84888900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024535545A Pending JP2024546877A (ja) | 2021-12-15 | 2022-12-14 | ヘテロ二量体リラキシン融合物を使用した治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250295737A1 (https=) |
| EP (1) | EP4447998A1 (https=) |
| JP (1) | JP2024546877A (https=) |
| KR (1) | KR20240121820A (https=) |
| AU (1) | AU2022410335A1 (https=) |
| CA (1) | CA3241355A1 (https=) |
| IL (1) | IL313386A (https=) |
| WO (1) | WO2023111112A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118510536A (zh) | 2021-11-11 | 2024-08-16 | 泰克托尼治疗股份有限公司 | 松弛素-2融合蛋白类似物及其使用方法 |
| CN120813595A (zh) | 2023-03-03 | 2025-10-17 | 阿斯利康(瑞典)有限公司 | 包含异源二聚体松弛素融合蛋白的药物制剂及其用途 |
| AU2024270919A1 (en) | 2023-05-18 | 2026-01-15 | Tectonic Operating Company, Inc. | Relaxin-2 fusion protein analogs and methods of using same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| ES2758994T3 (es) * | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| RU2014103288A (ru) | 2011-07-01 | 2015-08-10 | Байер Интеллектчуал Проперти Гмбх | Слитые полипептиды релаксина и их применение |
| KR20140039257A (ko) * | 2011-07-08 | 2014-04-01 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 릴랙신을 방출하는 융합 단백질 및 이의 용도 |
| EP3574004A1 (en) | 2017-01-25 | 2019-12-04 | Medimmune, LLC | Relaxin fusion polypeptides and uses thereof |
| CN115768801A (zh) * | 2020-05-08 | 2023-03-07 | 哈佛学院院长等 | 工程化松弛素及其使用方法 |
-
2022
- 2022-12-14 AU AU2022410335A patent/AU2022410335A1/en active Pending
- 2022-12-14 JP JP2024535545A patent/JP2024546877A/ja active Pending
- 2022-12-14 CA CA3241355A patent/CA3241355A1/en active Pending
- 2022-12-14 IL IL313386A patent/IL313386A/en unknown
- 2022-12-14 EP EP22839640.4A patent/EP4447998A1/en active Pending
- 2022-12-14 KR KR1020247023033A patent/KR20240121820A/ko active Pending
- 2022-12-14 WO PCT/EP2022/086001 patent/WO2023111112A1/en not_active Ceased
- 2022-12-14 US US18/720,279 patent/US20250295737A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024546877A5 (https=) | ||
| JP6877478B2 (ja) | 増殖分化因子１５（ｇｄｆ−１５）の構築物 | |
| JP2023530335A5 (https=) | ||
| JP2020196744A5 (https=) | ||
| US20250230241A1 (en) | Low ph pharmaceutical antibody formulation | |
| JP2017538395A5 (https=) | ||
| US5767260A (en) | Antigen-binding fusion proteins | |
| CA2505325C (en) | Stabilized single domain antibodies | |
| JP4175668B2 (ja) | Ｏｂ融合タンパク質組成物および方法 | |
| JP2019137675A5 (https=) | ||
| JP2023534143A5 (https=) | ||
| CN102906120B (zh) | 重组人g-csf二聚体及其在治疗神经系统疾病中的用途 | |
| JP2023554500A5 (https=) | ||
| JP2025148550A (ja) | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 | |
| JP2026053559A (ja) | ヘテロ二量体リラキシン融合物及びその使用 | |
| JP2025518227A (ja) | ｍａｚｄｕｔｉｄｅを使用する治療方法 | |
| JP2024546877A (ja) | ヘテロ二量体リラキシン融合物を使用した治療 | |
| JP2024544057A5 (https=) | ||
| JP2020504081A5 (https=) | ||
| JP2025116068A (ja) | 腎臓活性融合タンパク質及びそれを使用する治療方法 | |
| CN121127502A (zh) | 用于治疗肺高压的重组融合蛋白 | |
| US20100172909A1 (en) | Cerebral edema suppressant | |
| WO2002050118A2 (de) | Einzelketten-antikörper mit verbesserter stabilität | |
| Gras | Captopril en el tratamiento de la hipertension arterial esencial en el paciente diabetico. | |
| JP2025510774A5 (https=) |